https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-09-12 / Biol. Blood Marrow Transplant. 2016 12;22(12):2149-2154
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-09-12 / Biol. Blood Marrow Transplant. 2016 12;22(12):2149-21542016-09-12 00:00:002019-02-15 08:32:47Induction of Immune Response after Allogeneic Wilms‘ Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-08-24 / J. Biomed. Sci. 2016 Aug;23(1):64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-08-24 / J. Biomed. Sci. 2016 Aug;23(1):642016-08-24 00:00:002019-02-15 08:39:07A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-08-10 / Expert Rev Vaccines 2017 01;16(1):27-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-08-10 / Expert Rev Vaccines 2017 01;16(1):27-362016-08-10 00:00:002019-02-15 08:47:24Advances and challenges: dendritic cell vaccination strategies for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-29 / Ophthalmology 2016 10;123(10):2265-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-29 / Ophthalmology 2016 10;123(10):2265-72016-07-29 00:00:002019-02-15 08:49:46Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-25 / J Urol 2017 01;197(1):14-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-25 / J Urol 2017 01;197(1):14-222016-07-25 00:00:002016-07-25 00:00:00Immunotherapy for the Treatment of Urothelial Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-22 / Cancer Immunol. Immunother. 2016 09;65(9):1099-111
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-22 / Cancer Immunol. Immunother. 2016 09;65(9):1099-1112016-07-22 00:00:002019-02-15 08:45:42Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-21 / Onco Targets Ther 2016;9:4441-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-21 / Onco Targets Ther 2016;9:4441-512016-07-21 00:00:002023-03-07 11:15:56Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-19 / Clin. Cancer Res. 2017 Jan;23(2):399-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-19 / Clin. Cancer Res. 2017 Jan;23(2):399-4062016-07-19 00:00:002019-02-15 08:39:09PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-18 / Case Rep Med 2016;2016:9639585
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-18 / Case Rep Med 2016;2016:96395852016-07-18 00:00:002019-02-15 08:49:45Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-12 / Cytotherapy 2016 09;18(9):1178-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-12 / Cytotherapy 2016 09;18(9):1178-862016-07-12 00:00:002020-06-23 10:01:20Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group
